NCT03977454

Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty

Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty: a Single Center Randomized Controlled Trail (RCT) Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will assess if preoperative quadratus lumborum block (QLB)/lateral femoral cutaneous nerve block (LFCNB) with ropivacaine and glucocorticoids provide more effective analgesia than periarticular injection (PAI) with the same mixture in total hip arthroplasty (THA).

Detailed description

To support our hypothesis that preoperative quadratus lumborum block (QLB)/lateral femoral cutaneous nerve block (LFCNB) provides more effective analgesia than periarticular injection (PAI) in total hip arthroplasty (THA), we will look at the following outcomes: Primary outcome: Daily opioid consumption Secondary outcomes: Pain intensity and physical functioning while in the hospital: using pain inventory modified from Brief Pain Inventory and Length of hospital stays. Since both QLB/LFCNB nerve block and PAI techniques are both routinely used as standard of care anesthesia for THA, the study intervention will be the randomization to assign patients to one of these treatment options and assess their response from post-op patient questionnaires and data collection. When results were entered, the detailed description was updated to reflect the outcome measures used in the study.

Conditions

• Hip Arthropathy

Interventions

Type	Name	Description
PROCEDURE	Nerve Block	Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service. 1. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA 2. LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA
PROCEDURE	Periarticular Injection (PAI)	Intraoperatively, the surgeon will perform PAI per standard of care with the medications: 1\. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA
DRUG	Ropivacaine	60 ml 0.2% ropivacaine
DRUG	Dex	10 mg DEX/ 80 mg MPA

Timeline

• Start date: 2019-11-11
• Primary completion: 2021-06-19
• Completion: 2021-06-19
• First posted: 2019-06-06
• Last updated: 2022-09-23
• Results posted: 2022-09-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study